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Abstract
Genetic polymorphism is referred to the discontinuous interspecies genetic vari-
ability among individuals having distinct alleles on a particular locus. Genetic 
polymorphism of genes encoding drug-metabolizing enzymes constitutes individ-
ual’s susceptibility to drugs, affirmed by having discrete allelic frequencies by the 
individual, strengthening the concept of precision medicine. To combat with toxic 
 consequences of drugs, the polymorphic genes associated with xenobiotic metabo-
lism must be studied. Up to 70% xenobiotic elimination is believed to be depen-
dent on UDP-glucuronosyltransferase (UGT), an enzyme encoded by polymorphic 
UGT1A and UGT2B genes. Both bimodal and trimodal distribution patterns of UGT 
have been reported in various human populations studied. Genetic polymorphisms 
of UGT may even lead to truncated and shorter gene with grossly diminished enzy-
matic  activity. The extent of phenotypic alteration inflicted by genetic polymorphisms 
depends on its nature and position on gene locus. The different isoforms of UGT 
superfamily differ from each other regarding substrate specificity and selectivity. The 
incidence of genetic polymorphisms and associated altered gene functions results in 
 inter-individual variability in metabolic clearance and elimination of drugs. Hence, 
the critical interaction between genetics and biotransformation of drugs has recently 
been the focus of pharmacology research.
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1. Introduction
Pharmacogenetics enables the personalized therapeutics based on genetic profiling and 
describes Patient’s variation in response to therapy due to genetic factors. Pharmacogenetics 
© 2017 The Author(s). Licensee InTech. This chapt r is distributed under the terms of the Creative Comm s
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is the study of inter-individual differences in the sequence of particular genes affecting 
drug metabolism [1]. Genetic polymorphism is the variation in the sequence of DNA 
among populations and individuals. Inter-ethnic variations in drug response are con-
nected to  polymorphisms with racial populations showing discrete allele frequencies and 
inconsistency from each other [2–4]. Genetic polymorphisms may occur by chance and 
they may be caused by some agents such as chemicals, radiations or viruses. In the human 
genome, the most common source and simple form of genetic polymorphism are the sin-
gle-nucleotide polymorphism (SNP) and it contributes to 90% of human DNA polymor-
phisms. Genetic polymorphisms of drug- metabolizing enzymes (DMEs) can influence the 
biodisposition of drugs and thus alter the concentration of drugs in plasma and in target 
tissues [5].
In the human population, person-to-person variations in gene expression and functional 
activity of drug-metabolizing enzymes have been found to be associated with the change 
in their responses to toxicants, carcinogens and drugs [6]. Progress in pharmacogenetics has 
displayed that a series of drug-metabolizing enzymes have become essential to consider the 
biotransformation of drugs. Allelic variants with different catalytic functions have been rec-
ognized from common and wild-type allele as the number of drug-metabolizing enzymes 
is increased. In individualizing drug therapy, these specific genetic variants are valuable to 
phenotype/genotype an individual [7, 8]. Hence, the interplay of pharmacogenetics and bio-
transformation of drugs has recently been a focus of research.
2. Molecular bases
Genetic polymorphism within a population arises as a result of alteration in genes encoding 
metabolizing enzymes with a variant allele frequency of more than 1% [9]. For such genes, 
an allelic site has a number of single-nucleotide polymorphisms (SNPs) which may result in 
increased, reduced or even no enzyme function and their disrupted biological regulations 
through incorporating several mechanisms. A genotype is referred to a comprehensive study 
of an organism’s particular genetic make-up while the associated observable traits of an indi-
vidual describe its phenotype. However, keeping in view that a phenotype is influenced by 
the combination of genetic and environmental determinants, it may not always express a 
complete concordance with associated genotype [10].
3. SNPs and drug-metabolizing enzymes
Single-nucleotide polymorphism in genes of drug-metabolizing enzymes affects the response 
of drug to body and absorption, distribution, biotransformation, and excretion of drugs. 
These SNPs are a source of inter-individual and inter-ethnic differences. Some mutations in 
the  coding region cause amino acid change, which results in alterations of enzyme activity, 
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substrate selectivity and sometimes, protein stability. Ensuring functional differences causes 
different metabolizer phenotypes [11]. Pharmacogenetics analysis provides insight into mech-
anisms included in drug response, with the ultimate goal to achieve optimal drug efficacy and 
safety.
Drug-metabolizing enzymes (DMEs) have a significant role in biotransformation and final 
excretion of xenobiotics and drugs by increasing their hydrophilicity. Biotransformation of 
drugs is usually comprised of phase I (oxidation, reduction and hydrolysis) reactions carried 
out by cytochrome P450 enzyme, and phase II conjugation reactions involve glucuronidation 
by uridine diphosphate glucuronosyltransferases (UGTs), acetylation by N-acetyltransferase 
(NAT) and glutathione-S-transferase in the liver, with numerous proteins accountable for 
transportation. These phase I and phase II enzymes are highly polymorphic leading to varia-
tion in the level of enzyme expression in vivo [12].
The first polymorphism in drug-metabolizing enzyme was reported in patients more than 40 
years ago with the incidence of side effects after administration of a recommended therapeu-
tic dose of the drug [13]. An array of possible physiological and environmental factors has 
been assigned to human variability in drug response. The physiological features consist of 
hepatic and renal function, age, gender and bodyweight, whereas the environmental features 
include concomitant drug administration, contact to definite chemicals and dietary intake as 
well. Genetic factors have traced that individual’s body respond to drug therapy in a different 
way as some people are well tolerated while others have harmful effects [12].
4. SNP-mediated metabolic modulation
The uridine diphosphate glucuronosyltransferases (UGTs) exist in almost all living beings 
counting microorganisms (viruses, bacteria), animals, plants and humans. UDP-glucuronosyl-
transferase is a microsomal enzyme carrying the glucuronidation of several exogenous (differ-
ent carcinogens as well as drugs) and endogenous compounds (bilirubin; breakdown product 
of heme, hormones). Glucuronidation is a primary reaction for the removal of countless 
substrates and drug compounds. The genetic variations in UGT enzyme lead to its changed 
regulation and expression. The activities of UDP-glucuronosyltransferase contribute to phar-
macological and physiologic consequences [14].
In humans, a main drug-metabolizing reaction called glucuronidation is catalysed by uridine 
diphospho glucuronosyltransferase enzyme (EC 2.4.1.17). Glucuronidation is the conjuga-
tion of small lipophilic molecules with uridine diphosphate (UDP) as a sugar donor, altering 
them into more water-soluble metabolites and accounts for 40–70% of xenobiotic elimina-
tion approximately [15]. UDP-glucuronosyltransferases are primarily expressed in the liver 
but are also distributed in various organs of the body, including the heart, kidney, thymus, 
spleen, olfactory epithelium, brain, intestine, adrenal glands and lungs. The expression of 
UGT is known to be affected by genetic polymorphism, physiological and environmental fac-
tors like age, diet, disease state, induction and inhibition by chemicals [16].
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5. Classification of UGT
The superfamily UGT is divided into four subfamilies called UDP-glucuronosyltransferase 1, UDP-
glucuronosyltransferase 2, UDP-glucuronosyltransferase 3 and UDP-glucuronosyltransferase 
8. This classification is kept on sequence similarity at the level of amino acid. The isozymes of 
family UGT1A have the first exon that is spliced into two to five common exons and thus pro-
ducing a C-terminal and N-terminal domain. The gene-specific promoter region is possessed 
by each member of UGT1A family [17]. The 13 isoenzymes of UGT1A gene (9 functional and 4 
pseudogenes) are all originated due to alteration in exon 1 region of this gene located on chro-
mosome 2q37 and 6 isoforms of UGT2B subfamily emerge to be encoded by a rigid cluster of 
separate genes located on chromosome 4 in humans [18].
6. UDP-glucuronosyltransferases (UGTs)
The covalent conjugation of sugar with the small organic molecule is brought about by a super 
family UDP-glucuronosyltransferase (UGT). This superfamily of UDP-glucuronosyltransferase 
enzyme has been explored in microorganisms (bacteria), plants and animals evolutionarily 
conserved and adapted to combat with the dynamic interaction with lipid-soluble com-
pounds. The UDP-glucuronosyltransferases are protein in nature that is bound to the mem-
brane and is confined to the smooth endoplasmic reticulum (SER) and nuclear compartment 
of the cell. They have a significant role in glucuronidation of many antibiotics and xenobiotics 
[14]. UGTs are synthesized as approximately 530 residues precursor containing an N-terminal 
signal peptide [19].
The mammalian UGT superfamily comprises of four families, and members of each of four 
families can also be recognized in various lower vertebrates. The UGT superfamily comprises 
of all glucosyltransferases that contain the UGT signature sequence (FVA)-(LIVMF)-(TS)-(HQ)-
(SGAC)-G- X(2) -(STG)-X(2)- (DE)-X(6)-P-(LIVMFA)-(LIVMFA)-X(2)-P-(LMVFIQ)- X(2)- (DE)-
Q, (X is any amino acid) [20], and add sugar to small lipophilic compounds. Glucuronidation 
of compounds forms a range of glucuronides containing functional groups (O-, N-, S- and C-), 
which significantly enhance the solubility of the parent drugs and terminates its biological 
effect [21].
7. Distribution of UDP-glucuronosyltransferases
Approximately, the drugs from all therapeutic classes containing an extensive range of accep-
tor groups pass through glucuronidation process. However, non-steroidal anti-inflammatory 
drugs and analgesic agents are usually metabolized by this mechanism. It is well recognized 
that the liver has the maximum abundance and array of UDP-glucuronosyltransferases [22, 
23]. The members of UGT1A and UGT2B subfamilies are also found in many other tissues 
and organs incorporating the epithelium, brain, nasal cavity, stomach, small intestine, colon, 
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kidneys, lungs, ovaries, mammary glands, testis and prostate gland, in addition to hepatic 
abundance [16, 23]. The kidneys and GIT (gastrointestinal tract; stomach, small intestine and 
colon) are the most important extra-hepatic sites in case of drug metabolism [24]. All mem-
bers of the UGT1A and UGT2B families are expressed differentially in human liver with the 
exception of some members of both families including UGT1A5, 1A7, 1A8, 1A10 and 2A1 [25]. 
In contrast to the UGT1A and UGT2B, members of UGT3 family are principally expressed in 
thymus, testis and kidney with nearly untraceable expression in liver and GI tract [26].
8. Types of glucuronides
The UDP-glucuronosyltransferase enzyme catalyses the transfer of sugar glucuronic acid 
(GA) from uridine-diphospho-glucuronic acid (UDP-GA) to various exogenous as well as 
endogenous compounds containing hydroxyl, thiol, amine, carbonyl, carboxylic and hydrox-
ylamine due to structural diversity of the substrates. Binding with glucuronic acid is a 
quantitatively most important phase II reaction and is a primary pathway in nature for detox-
ification of a wide range of drugs, dietary compounds, cancer causing agents and their oxi-
dized metabolites, and a variety of environmental chemicals and thus excreting lipid-soluble 
waste compounds from the body in urine and bile [27, 28]. Glucuronidation of compounds 
forms a range of glucuronides containing functional groups (O-, N-, S- and C-) which sig-
nificantly enhance the solubility of the parent drugs and terminates its biological effect [21].
Substrates containing different functional groups chemically form different glucuronides 
like aliphatic alcohols and phenols form ether glucuronide, while those containing a COOH- 
group form ester glucuronides (acyl glucuronides). The compounds, which possess both 
Polymorphic enzymes Endogenous 
cofactor
Biochemical 
reactions involved
Specific substrate Intermediate 
metabolites
References
Sulfotransferase (SULT) Sulfate Sulfation Salbutamol Salbutamol 
sulfate
[30]
UDP-
glucuronosyltransferase 
(UGT)
UDP 
glucuronic acid
Glucuronidation Morphine Morphine-3-
glucuronide
[31]
Glutathione-S-transferase 
(GST)
Glutathione Glutathione 
conjugation
Doxorubicin Glutathione 
metabolite
[32]
N-acetyltransferase 
(NAT)
Acetyl-CoA Acetylation SMX, caffeine N-Ac SMX AFMU [33, 34]
Methyltransferase (MT) Methyl Methylation Mercaptopurine, 
captopril
Methyl 
metabolite
[35]
Table 1. Important polymorphic human DMEs, cofactors, biochemical reactions, substrates and their intermediate 
metabolites.
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phenolic and COOH- groups, can be transformed into both ether and ester glucuronides such 
as mycophenolic acid (MPA). Glucuronidation of amines (primary, secondary and tertiary) 
and sulfhydryl compounds result in the formation of N-glucuronides and S-glucuronides, 
respectively, whereas C-glucuronides are obtained from compounds containing carbonyl 
group. The most common and rare drug glucuronides in humans are O-glucuronides and 
C-glucuronides, respectively [29].
There are many enzymes in humans that are polymorphic in nature and metabolize a variety 
of drugs through biotransformation reactions presented in Table 1.
9. UGT isozymes
The large substrate specificity of each UGT isoform makes possible the glucuronidation of 
structurally isolated molecules. In humans, roughly (40–70%) drugs administered clinically 
undergo glucuronidation [36]. In humans, 19 UGT isoforms have been recognized, expressed 
and differentiated: 9 UGT1A members encoded by the UGT1A gene locus are positioned on 
chromosome number 2 and nine members of UGT2B family (7 members of UGT2B and 2 
members of the UGT2A subfamily) are located on chromosome 4. The isoforms of the UGT1A 
and UGT2B families have a key role in dispensing lipophilic compounds because of their 
ability to glucuronidate an extensive array of structurally different substrates. Different UGT 
isoforms are involved in the formation of drug glucuronides but they reveal overlapping 
and unusual substrate selectivity and specificity. Individual UGTs differ from each other 
in sense of regulation and expression. UGT activity is known to be affected by physiologi-
cal and environmental factors like age, diet, disease state, induction and inhibition of UDP-
glucuronosyltransferase by chemicals, ethnicity, genetic polymorphism and hormonal level 
[37]. Some general conjugation reactions of glucuronidation carried by UGT are expressed 
through chemical equations A–F, given below [38].
A. R -OH + UDP -GA → UDP + R -O-GA
B. R – SH + UDP -GA → UDP + R - S-GA
C. R -NH
2
 + UDP-GA → UDP + R NH−GA
D. R –CHO + UDP-GA → UDP + R -CO-GA
E. R -COOH + UDP-GA → UDP + R –CO−(OGA)
F. R -NHOH + UDP-GA → UDP + R -N−(OH)GA
10. Structural organization of UDP-glucuronosyltransferase 1
The UGT1A isoforms are encoded by a single intricate and complex locus that is organized 
similarly in all mammals. The nine functional proteins are encoded by UGT1A gene locus 
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(1A1, 1A3, 1A4, 1A5, 1A6, 1A7, 1A8, 1A9 and 1A10). In humans, the UGT1A gene size is about 
200 kb located on chromosome 2q37 and encodes 13 isozymes. Each isoform has a distinctive 
promoter region, unique exon-1, and shares (2–5) four common exons [39]. Transcription is 
commenced at unique promoter. Consequently, each of the 13 transcripts has a unique 5′ 
end and a similar 3′ end, which is engaged in identification of the UDP-sugar molecule. The 
human UGT1A isoforms can be divided into four groups on the basis of sequence resemblance, 
amplification and divergence of gene: UGT1A1, UGT1A6 and UGT1A2P to 1A5 cluster and 
UGT1A7 to 1A13P cluster. Exons of UGT1A1 and UGT1A6 made proteins that are nearly 50% 
alike; conversely, within exons of 1A2P–1A5 and 1A7–1A13P clusters, the resulting proteins 
are more than 90% identical [17]. Four members (1A2P, 1A11P, 1A12P and 1A13P) of UGT2A 
subfamily have been recognized as pseudogenes since they have mutations that would avert 
their translation into functional proteins. It has been observed that complexity to the UGT1A 
locus produces another form of the common exon 5 so-called as 5b exon that can be merged 
into the human UGT1 proteins. The alternative forms produce mRNAs that encode smaller 
polypeptides of each UGT1 protein. These smaller proteins do not have a transmembrane part 
but keep their ability to confine themselves to smooth endoplasmic reticulum. These small 
UGT1 forms are non-functional and can heterodimerize with whole UGT1 form and lack 
their activity [40]. In human tissues, short-form UGT1 transcripts are largely distributed and 
expressed at considerable levels [41].
11. Function/effect of UGT1A isoforms
UGT1A1 is the most important isoform of UGT1A gene that brings about the glucuronida-
tion of bilirubin (a breakdown product of haemoglobin) which required to be eliminated 
from the body. Genetic alterations in the UGT1A gene are presumed to have an intense effect 
on the health of affected individuals, particularly those that modify UGT1A1 activities and 
correspond to rare mutations. Sixty rare mutations have been well known as point muta-
tions, deletions and insertions in UGT1A1 gene. Only a small number of these mutations are 
reported in common population with high frequency (up to 41%). These mutations called 
polymorphisms in TATA box region of UGT1A1 promoter produce variant alleles that lead 
to decrease in activity and rate of glucuronidation by UDP-glucuronosyltransferase [42–44]. 
These mutations in the UGT1 gene are correlated with two forms of the unconjugated hyper-
bilirubinemia syndromes. The wild type and common variant allele include six and seven 
repeats, respectively [45]. The UGT1A isoforms appeared to be expressed at a lower level in 
different populations of the world: approximately 0–3% in the Asian population, 2–13% in 
Caucasian population and up to 16–19% in Africans [44].
Paracetamol is being used as a probe drug to study slow and fast acetylation capacity of human 
[46], which is mainly cleared by hepatic glucuronidation from the body. Inter-individual vari-
ability in capacity to glucuronidate paracetamol and possible risk for liver damage could be 
explained by polymorphisms in genes encoding the paracetamol glucuronidation [47].
Court et al. used human liver samples for accessing paracetamol glucuronidation activ-
ity by UGT isoforms (1A1, 1A6, 1A9 and 2B15) that chiefly glucuronidate paracetamol. 
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Three single-nucleotide polymorphisms (rs10929303, rs1042640 and rs8330) positioned in 3' 
untranslated region of UGT1A1 were found to be associated with paracetamol glucuronida-
tion activity. Consistently the highest glucuronidation activity is observed with SNP rs8330. 
This single-nucleotide polymorphism did not modify stability of mRNA and translation 
capacity [48].
In the pharmacokinetic studies, acetaminophen and SN-38 were used as phenotyping probes 
in vivo to check glucuronidation activity. Study subjects were given irinotecan and acetamino-
phen separately after a specific wash out period, and no association was observed between 
irinotecan and acetaminophen glucuronidation activity, proposing affinity for many different 
UGT1 isoforms [49, 50].
12. UDP-glucuronosyltransferase 2
The UGT2 gene family is further divided into two subfamilies on the basis of sequence resem-
blance: UGT2A and UGT2B. The genes in each subfamily usually have more than 70% sequence 
resemblance. The great level of resemblance makes it complex to establish orthologous asso-
ciations between species in each subfamily. Therefore, a sequential numbering system based 
on their chronological order of discovery has been used for UGT2 genes [20]. In the human 
genome, the UGT2 family comprises of three UGT2A and six UGT2B members. The members 
of UGT2A subfamily are called pseudogenes as they do not form functional proteins. The 
members of UGT2B subfamily are encoded by separate and independent genes, including 
UGT2B4, UGT2B7, UGT2B10, UGT2B11, UGT2B15 and UGT2B17. The UGT2B genes emerge 
to be encoded by a firm group of genes located on chromosome number four [18].
The members of UGT2 family are supposed to be developed by replication of whole UGT2 
gene. UGT2A3 gene has six distinct exons. However, UGT2A1 and UGT2A2 genes have a 
variable and shared exon structure similar to that of the UGT1A family. The UGT2 members 
also have first unique exon and a set of five shared (2–6) exons. The first 2 exons of each UGT2 
gene encode a region of 241 amino acids similar to that of UGT1A gene locus [51].
13. Function and effect of UGT2B genes
UGT2B4 gene of UGT2 family plays an important role in biotransformation and glucuronida-
tion of bile acids allowing their glucuronide efflux from hepatocytes via transporters such as 
multi-drug resistance-associated protein (MRP) 2 or MRP3 [52] and detoxification of many 
phenols [18, 53].
UGT2B4 gene is expressed in the chief metabolizing organ: liver and in several extrahe-
patic tissues [18, 54]. Polymorphism in the co-substrate binding region of UGT2B4 gene 
resulted in mutant allele, which causes change in position of amino acid from aspartate to 
glutamate at 458 codons [54]. The single change in position of amino acid alters the rate 
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of glucuronidation. This variant allele is present in the Caucasian, African and Hispanic 
populations at a frequency varying between 0.17 and 0.38, whereas it is absent from the 
Asian population [54–56]. Lampe et al. used human liver samples to study polymorphisms 
in UGT2B4 gene. These polymorphisms cause a change in position of amino acids: from 
phenylalanine to leucine at codons 109 and 396. It was found that these polymorphisms are 
rare because they were absent in a big group of 272 individuals [56].
UGT2B15 gene showed glucuronidation activity towards steroid hormones, a number of 
classes of drugs and their metabolites [57–60]. A guanine to thymine replacement at codon 85 
causes an amino acid change from aspartate to tyrosine in substrate binding site of UGT2B15 
gene. The homozygous wild-type allele is not common in Caucasians as compared to the Asian, 
Hispanic and African populations. On the whole, 19–32% of the studied population have been 
found to bear homozygous variant allele. Levesque et al. studied the effect of UGT2B15 gene 
polymorphisms on function and enzyme activity in vitro using liver microsomes. The homo-
zygous variant allele presented same reaction constant (K
m
) values but the rate of reaction 
(V
max
) is two times different for steroid hormones [58]. Court et al. determined the functional 
impact of UGT2B15 variants towards catalytic activities in HEK 293 cellular fractions by using 
S-oxazepam as probe drug. The glucuronidation activity of homozygous wild-type allele for 
S-oxazepam was five times more than homozygous variant allele UGT2B15*2 [59].
Figure 1. Schema representing the genetic polymorphic pattern of human UGT1A & UGT2B genes.
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Lampe et al. evaluated the rate of recurrence of the UGT2B4, UGT2B7 and UGT2B15 poly-
morphisms in Caucasian and Asian individuals. For all polymorphisms, the genotype and 
allele frequencies were considerably different in both populations. The distribution of the 
genotypes also differed by ethnic group. All Asians were homozygous for common allele, 
and incidence of wild-type allele is two times higher in them as compared to Caucasians [56].
Navarro et al. investigated the effect of UGT1A6 and UGT2B15 genotypes on paracetamol gluc-
uronidation in a controlled feeding trial. 1000 mg paracetamol was administered to healthy 
volunteers orally, and saliva and urine samples were collected for determining the concen-
tration of paracetamol and its metabolites. The concentration of unchanged paracetamol is 
higher in men as compared to women who had more paracetamol glucuronide. The percent-
age of unchanged paracetamol is higher in individuals with homozygous common allele rela-
tive to heterozygote and homozygous variants. The UGT2B15 gene considerably affected the 
paracetamol glucuronidation while the involvement of UGT1A6 in paracetamol glucuronida-
tion was moderate [61].
Mutlib et al. demonstrated the importance of UGT1A and UGT2B15 genotypes: 1A1, 1A6, 
1A9 and 2B15 on paracetamol glucuronidation. It was observed that UGT1A1 and UGT2B15 
contribution was highest in conjugating paracetamol [62]. The polymorphic variations in 
UGT1A and UGT2B genes are presented in Figure 1.
14. UDP-glucuronosyltransferase 3
The third family of UGT superfamily is UGT3A that consists of two genes: UGT3A1 and 
UGT3A2. It is situated in a 115 kb piece of chromosome number 5p13. Each gene of this fam-
ily includes seven unique exons that are just about 30 kb size and encodes 523 amino acids 
of protein. At protein level, both genes are 80% similar which shows larger conservation of 
sequence in UGT3A than that found in UGT1A and UGT2B families [63].
15. UDP-glucuronosyltransferase 8
The fourth family of UGT superfamily is UGT8 gene family. This family is composed of a 
single gene which contains five exons and is situated on chromosome number four (4q26) 
together with genes that encode other phase II enzymes. The UGT8 gene is greatly conserved 
and does not involve in the biotransformation of drugs. This is due to its partial expression in 
the brain where exposure to xenobiotics is restricted [51].
16. Genotype-dependent functional polymorphism
In the human population, individual-to-individual variations exist genetically in UGT 
activity and are phenotypically divided as rapid or slow glucuronidator. On the basis of 
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UDP-glucuronosyltransferase activity, humans are divided into bimodal and trimodal dis-
tributions. In bimodal distribution, humans are categorized as fast and slow glucuronidators 
or fast, intermediate and slow glucuronidators in trimodal distribution. UGT1A and UGT2B 
subfamilies exhibit overlapping but different substrate specificities and variable levels of 
expression in different organs [16, 36, 64, 65].
An increasing integer of functional single-nucleotide polymorphisms (SNPs) is identified 
in humans at UGT1A gene locus with a potential relevance for drug therapy. A single-
nucleotide polymorphism or a combination of multiple nucleotide substitutions and inser-
tion or deletion is responsible for allelic variants of UGT (UGT1A and UGT2B) [66]. The 
most common isoforms of UGT associated with drug metabolism are UGT1A1, 1A6, 1A9 
and UGT2B4, UGT2B15. Many studies have described associations between specific phe-
notypes for UGT polymorphic enzyme and susceptibility to cancer, particularly lung and 
bladder, breast cancer, Parkinson’s disease and the autoimmune disease systemic lupus 
erythematosus. These associations may be due to differences in the ability of enzyme phe-
notypes to activate or detoxify chemical toxins or, alternatively, to linkage disequilibrium 
where a particular allele coding for another gene with a direct role in determining disease 
susceptibility shows genetic linkage with an allelic variant of the xenobiotic-metabolizing 
enzyme [67].
Genetic polymorphisms lead to truncated and shorter gene which efficiently diminishes 
enzymatic activity and even a single mutation alone can account for decrease or increase 
in enzymatic regulation. On the other hand, increased and elevated enzymatic activity 
may be due to elevated mRNA stability [59]. The expression and activity of UGT increase 
during childhood and adolescence. Many cis factors (polymorphism) and trans-factors 
including transcription factors (TFs) and nuclear receptors (NRs), miRNA targeting and 
other epigenetic regulating factors play an important role in the regulation of UGT enzyme 
expression. In the liver, transcription levels of UGTs determine their activity. The tissue 
specific and ligand-activated TFs and NRs play a chief role in the expression of UGTs by 
binding to cis-regulatory elements. The ontogeny of drug-metabolizing enzymes is analo-
gous by the maturation of organ systems among children and has intense effects on drug 
disposition [68].
In the beginning, UGT1A and UGT2B families assumed to be evolved as consequences of 
their neutralizing function against noxious chemical at the hepatic and gastrointestinal 
barrier. Regulation of UGTs may have developed along with some other drug-metabo-
lizing enzymes (DMEs) in the course of animal and plant competition [69]. The families 
expanded in different ways on different chromosomes, but similar exon-intron struc-
tures encode a protein family with similar functional architecture despite the amino acid 
sequence diversity [70]. UGTs performed their functions at pre-systemic, systemic level 
and locally in cells.
Glucuronidation by UGT provides a critical detoxification pathway for exogenous com-
pounds and drugs from several therapeutic classes, including analgesic and non-steroidal 
anti-inflammatory agents, anticonvulsants, antipsychotics, anti-viral agents and benzodiaz-
epines [27, 28, 71].
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17. Role of UGT isoforms in metabolism
Some substrates and drugs are fairly selective for a particular UGT enzyme as the endog-
enous molecule; bilirubin is particularly glucuronidated by UGT1A1 enzyme. However, the 
bulk of substrates (small and hydrophobic molecules) are often metabolized by several UGT 
isoforms [72], thus making it complex to recognize which UGT enzyme is primarily account-
able for the glucuronidation of compounds. The accessibility of individual cDNA has made 
it possible to study the function of each UGT enzyme, even though the quantitative varia-
tions in the rate of reaction might be present based on their expression [28]. Moreover, there 
are facts and figures which designate that UDP-glucuronosyltransferase enzymes are linked 
as homo and hetero-oligomers in vitro and in vivo. Oligomerization may be necessary for the 
activity of the UGT enzymes and sometimes it may even vary the rate of the biotransforma-
tion [65, 72]. Formation and disposition of glucuronides in cells and even in the whole organ-
isms are under control of several factors. However, the activity of isoform-specific substrate 
in vitro associates very well with activity in vivo and is appropriate for the anticipation of 
metabolic detoxification in vivo [73, 74]. The functional significance of numerous UGT iso-
forms is ambiguous for many reasons: substrate specificity of isoform is weak displaying 
overlapping substrate specificity and substrate conjugating regions of UGT enzymes have 
not been recognized [75].
Lampe et al. found that individuals possessing homozygous variant allele of UGT1A1 
and UGT1A6 isoform presented abnormality in the conjugation of a variety of drugs. In 
Tankanitlert’s study, the combined effect of UGT1A1 and UGT1A6 genes was investigated in 
thalassemic patients. Thalassemic patients were grouped into three categories. It was figured 
out that there is no difference in glucuronidation capacity of patients with homozygous wild-
type allele and those who were heterozygous, but rate of glucuronidation is lower in patients 
with variant alleles signifying that variant alleles are a potent modifier of acetaminophen 
glucuronidation [76].
In the human population, wide variations are found in their glucuronidation capacity of 
drugs. The extent of variations can range from 3-fold to more than 100-fold, considering the 
studied drug. Many genetic and environmental factors act discretely and in combination to 
produce broad inter-individual differences. Phenotype-like glucuronidation capacity of UGT 
is not separated from genotype but somewhat displays continuous and overlapping changes 
due to multiple interacting environmental and genetic factors [77].
In general population, polymorphisms in phase I and phase II drug-metabolizing enzymes 
lead to differences in enzyme expression level. This variability in enzyme expression is due 
to the presence of genetic polymorphisms and mutations in the wild-type gene, resulting in 
impaired or reduced activity of the enzyme. Individuals having mutated enzymes may differ 
from normal individuals in their vulnerability to certain diseases. Some specific phenotypes 
for these polymorphic enzymes are related to increased vulnerability to cancer, predominantly 
lung, bladder cancer and Parkinson’s disease. This altered enzyme activation or certain chemi-
cals including constituents of tobacco, xenobiotics and neurotoxin initiate these diseases [78].
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Biotransformation is a key process in the body that finds out the pharmacokinetics of an 
administered drug. Several factors, which control the level of biotransformation, include 
physiological state of the patient, genetics and co-administered drugs, and these may cause 
the toxic or sub-therapeutic concentration of drugs. The large inter-individual variability is 
gradually accumulating in glucuronidation due to underlying genetic mechanisms but a few 
polymorphisms have been described in UGTs with probable clinical relevance. The polymor-
phisms can lead to altered drug clearance with a clinically relevant phenotype. However, the 
proof in vivo for such a link is very weak [36].
18. UGT SNPs and disease
Human UDP-glucuronosyltransferase enzyme was appeared to be polymorphic genetically. 
Genetic polymorphisms in this enzyme are unlikely to participate in toxicity of drugs since the 
isozymes illustrate broad overlapping specificity and tissue distribution [79]. Polymorphisms 
lead to varying degree of transcriptional as well as functional variations that might reduce the 
activity of UGT enzyme and consequently affected individuals present some sort of pathol-
ogy. The polymorphisms in UGT1A and UGT2B gene families were also suggested to change 
the risk of diseases either due to reduced inactivation of hormone or as a result of decreased 
detoxification of carcinogenic chemicals and production of their reactive conjugates [64].
The variant alleles of UGT1A1 gene result in some syndromes associated with the diminish-
ing bilirubin conjugation capacity of UGT1A1 isoform. Kadakol et al. summarized the data of 
approximately 50 polymorphisms of UGT1A1 gene contributing to Crigler-Najjar syndrome 
type I and II. Crigler-Najjar syndrome type 1, also known as non-hemolytic jaundice, is 
entirely deficient of UGT1A1 activity due to which bilirubin exerts toxic effects on brain [80]. 
One of the widespread diseases caused by inactivity of UGT1A1 gene is Gilbert’s syndrome. 
More than 10% of the population suffered from this localized chaos was differentiated by 
sporadic unconjugated hyperbilirubinemia. This syndrome is associated with polymorphism 
in the promoter region of UGT1A1 enzyme [45]. In patients with Gilbert’s syndrome, when 
irinotecan drug was administered, it resulted in increased toxicity of an active metabolite of 
SN–38 because in these patients, UGT1A1 gene is not functional as it is responsible for the 
formation of inactive glucuronide of irinotecan [81].
Several studies assessed the function and differential expression of the UGT1A isoforms in the 
colon [82], liver [83], pancreas [84] and kidney cancers [85]. The inquiry of a case-controlled 
study exposed that individuals carrying variant alleles of UGT1A gene were at increased risk 
of having colorectal cancer [86]. In two independent studies, it was investigated that polymor-
phisms in promoter and coding regions of UGT1A isoforms were correlated with the toxicity 
of irinotecan drug in Japanese cancer patients and with neutropenia [66, 87].
Yilmaz et al. examined the association between mRNA expression of UGT (1A3 and 1A7) 
isoforms and pancreatic cancer. Healthy and tumour samples were collected from pancre-
atic patients. The mRNA expression of both isoforms of UGT1A gene was notably higher 
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in pancreatic cancer tissue than normal healthy tissue, and this high expression was also 
linked with tumour size and its progression [88].
Cengiz et al. reported that expression of UGT1A genes was different in healthy normal and 
tumour cells of patients suffering from stomach cancer. This differential expression might 
affect the growth and progression of a variety of cancers [89]. Several authors studied the 
role of UGTs in breast cancer risk and incidence in different populations. They focused on the 
expression of isoforms of UGT1A gene by using cell lines of breast cancer and concluded that 
women with mutations in UGT1A1 enzyme were at higher risk of developing breast cancer 
due to its reduced activity but no relationship was observed between estrogen receptor status 
and UGT1A1 genotype [44, 90].
Bigler et al. examined the function of UGT1A6 polymorphisms in healthy controls and 
patients of colon adenoma in the context of aspirin use. A conflicting association was found 
between aspirin users’ colon adenoma patients and the UGT1A6 variants [82]. Several stud-
ies have explored the relationship between polymorphisms of UGT1A7 gene and colorectal, 
hepatocellular carcinoma and lung cancer in Japanese [91, 92], Chinese [83], Caucasian [93], 
French [94] and Koreans [95] with reduced incidence of common wild-type allele [96].
19. Risk assessment with SNPs
Uridine disphospho glucuronosyltransferase (UGT1A and UGT2B) enzyme contribute to the 
removal of miscellaneous drugs, environmental chemicals and endogenous compounds [27, 
28]. The majority of human uridine disphospho glucuronosyltransferase enzymes metabolize 
aliphatic alcohol and phenol compounds of low molecular mass. Most of UGT genes contain 
single-nucleotide polymorphisms (SNPs) those altered drug metabolism, excretion and drug 
function and have been found to be associated with Crigler-Najjar syndrome type 1 and 2, 
hyperbilirubinemia and Gilbert’s syndrome. It is believed that SNPs in regulatory regions 
have the highest impact on phenotype [97].
MacLeod et al. observed that the individuals with elevated level of androgens might be at 
higher risk of prostate cancer due to presence of lower activity allele [98]. An independent 
case-control study verified that the patients of prostate cancer with homozygous variant allele 
had lower enzymatic activity [99]. A positive association has been reported between prostate 
cancer risk and low-activity UGT2B15 allele or a complete UGT2B17 deleted gene [99, 100]. The 
UGT2B15 gene is recognized to be greatly expressed in cell lines of prostate cancer [58, 101], 
and a noteworthy involvement was found between the UGT2B15 homozygous variant geno-
type and cancer recurrence [102]. The UGT2B15*2 variant allele appeared to be a risk factor for 
the incidence and poor subsistence of patients of breast cancer. It was reported in breast cancer 
patients who had mutations in more than one drug-metabolizing enzymes as one UGT2B15*2 
allele and also the SULT1A1*2 allele had mainly reduced survival rates of five years.
In humans, uridine diphospho glucuronosyltransferase 2B (UGT2B) proteins facilitate 
the elimination of testosterone hormone in form of glucuronide metabolites. Grant et 
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al. evaluated the association between UGT2B15 and UGT2B17 genes of UGT2B family 
relative to plasma levels of androgens and development of cancer in Whites and Blacks. 
An association was determined between copy number variant of the UGT2B17 gene and 
plasma androgen levels in Whites, but surprisingly, no association was found in Blacks 
[103].
A number of glucuronides are known to acquire pharmacologically useful and harmful activ-
ities. Morphine is mainly cleared from the body by glucuronidation pathway and possessed 
two binding domains [38]. The morphine-3-glucuronide (M-3-G) is the main glucuronide and 
is a powerful inhibitor of morphine [31, 104]. The deposition of M-3-G reduces the effective-
ness of morphine and exerts excitatory effects on the central nervous system [105]. Decreased 
glucuronidation of morphine to morphine-6-glucuronide in vivo was associated with poly-
morphisms in UGT2B7 gene [106].
Navarro et al. [61] evaluated the impact of UGT1A6 gene and dietary inducers on uri-
nary excretion of aspirin in Caucasians and Asians. They undertook this study on healthy 
264 men and 264 women aged between 21 and 45 years. These healthy volunteers were 
administered 650 mg aspirin, and their urine samples were collected at predetermined 
time intervals. Considerable variation was found in excretion pattern of aspirin between 
sexes and ethnicities. Asians excreted more aspirin, salicylic acid acyl-glucuronide and 
salicylic acid phenolic glucuronide as compared to Caucasians. Diet might manipulate 
the excretion of aspirin but effects were due to binding of glycine endogenous molecule 
rather than glucuronic acid. In another study, the glucuronidation of aspirin was under-
taken in relevance to UGT isoforms: 1A1, 1A3, 1A4, 1A6, 1A7, 1A8, 1A9, 1A10, 2B4, 2B7, 
2B15 and 2B17. It was analysed that all UGT isoforms conjugated aspirin except UGT1A4 
and UGT2B17 [107].
Two polymorphisms in exon 1 region of UGT1A6 gene resulted in amino acid substitutions, 
and these substitutions were likely to be related to reduce enzyme activity towards numerous 
phenolic compounds [108]. UGT2B15 gene catalyses the metabolism of multiple substrates, 
thus enhancing their clearance from the body [60].
20. Conclusion
Many polymorphisms have been reported for UGT1A and UGT2B genes and new polymor-
phisms are continuously evolving. These polymorphisms affect the phenotype and extent 
of variation depends on the nature of the polymorphisms and their position in the gene. 
Knowledge about genetic polymorphisms underlying the extensive inter-individual dif-
ferences in glucuronidation process is progressively gathering but only a small number of 
polymorphisms in UDP-glucuronosyltransferase enzyme have been reported with possible 
clinical significance. Patients possessing different genetic polymorphisms illustrated lower or 
even diminished glucuronidation of a wide range of drugs from almost all therapeutic classes. 
The incidence of polymorphisms is variable in different populations of the world for various 
isoforms of UGT1A and UGT2B.
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Classification of UGT implicated in phenotyping reaction of a compound depends upon 
the activity of UGT, the expression and the incidence of glucuronidation rate. But the ever-
increasing accessibility of agonists and antagonists probes for individual UGTs provides 
the dependable prospect for glucuronidation phenotyping. Moreover, many factors affect 
the functions and activities of UGT proteins in vivo such as age (i.e. neonatal period), con-
sumption of alcohol, smoking of cigarette, diet and nutritional habits, pathological condition, 
ethnicity, hormonal factors and polymorphisms of genes (i.e. occurrence or frequency). The 
techniques required for glucuronidation phenotype of UGT enzymes have been developed 
extensively with the discovery and differentiation of specific and selective probes (substrates 
and inhibitors), accessibility of recombinant UGT enzymes and optimization of incubation 
states necessary for measuring glucuronidation of drugs.
The tissue-specific expression of each UGT1A and UGT2B isoforms is the subject of genetic poly-
morphisms, and these individual isoforms can be induced and inhibited by drugs. The individual 
isoforms differed from each other in sense of substrate specificity and selectivity, the incidence of 
genetic polymorphisms and gene functions that resulted in broad inter-individual variability in 
metabolic clearance. It is apparent that polymorphisms in the coding and regulatory segments of 
all UGT enzymes are likely to be altered their functions and expression. In addition, induction of 
metabolism may increase the clearance of therapeutic agents, leading to sub-therapeutic expo-
sures and lack of pharmacological effect. Alternatively, inhibition of metabolism may reduce the 
clearance of drugs and lead to supratherapeutic exposures, resulting in undesired side effects or 
toxicity.
Variation in DNA sequence results in SNPs, and analysis of SNPs in diseases allows inves-
tigation of the influence of genetic polymorphisms on disease vulnerability, drug resistance 
and eventually the health care. The study of SNPs provides a potent resource for establish-
ing a relationship between a phenotype and regions of the DNA. Genetic polymorphism are 
sources of variations at all levels. Genetic polymorphism of genes encoding phase I and phase 
II enzymes describes inter-individual variability in the biotransformation of xenobiotics.
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